Performance Reviews: Critiques, Legal Implications, and Tips for Effective Use

In a series of major industry milestones, this week it was announced that the investigational drug Exilby, a standardized full-spectrum extract from a proprietary cannabis strain, has received marketing authorization from Germany for the treatment of chronic low back pain with a neuropathic component while late last month the United States Food & Drug Administration granted the medicine a Breakthrough Therapy Designation intended to expedite the development and evaluation of the drug. It is positioned as the first non-opiate chronic pain treatment of its kind worldwide.

On May 19, 2026, the Securities and Exchange Commission proposed two sets of amendments—one expanding the accessibility of smaller reporting companies to financing opportunities and the other simplifying the reporting framework for public companies.

The SBA’s proposed 8(a) rule removes presumptions of social disadvantage. Learn what it means for applicants, planning timelines, and compliance strategy.